China Healthcare Weekly (Jun.29) - Biotech Valuation Bubble Is About to Burst, Innovent's Placement

412 Views29 Jun 2025 09:19

The valuation bubble of innovative drug companies may burst soon, with some founders/shareholders already cashing out. Innovent's Placing Price of HK$78.36/share is expensive. Wiser to offload not buy

What is covered in the Full Insight:

Introduction to Valuation Concerns
Industry Viewpoints and Market Projections
Innovent's Placement and Financial Performance
R&D Prospects and Pipeline Highlights
Market Review and Risks

Xinyao (Criss) Wang

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 4-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream